Literature DB >> 6884166

Absorption of contrast medium during ERCP.

R A Sable, W S Rosenthal, J Siegel, R Ho, R H Jankowski.   

Abstract

In order to assess systemic absorption, serum diatrizoate levels were measured in 25 patients requiring endoscopic retrograde cholangiopancreatography (ERCP). Urinary diatrizoate was measured in the urine of seven of these. In five additional patients, diatrizoate was instilled into the duodenum during endoscopy. Blood was drawn before and after completion of the procedure in all patients and at intervals from 2 to 24 hr in nine. Eighteen-hour urine collections were obtained from seven patients. Increases in serum diatrizoate concentration were 7.10 micrograms/ml +/- 3.01 (mean +/- SE) in the duodenal-instillation patients, 230.68 +/- 53.24 micrograms/ml in 9 patients in whom only the pancreatic duct was visualized, 7.83 +/- 1.05 micrograms/ml in three patients in whom only the bile duct was visualized, and 77.67 +/- 28.22 micrograms/ml in 13 patients in whom both ducts were visualized. The mean total urinary excretion of diatrizoate was 3.05 +/- 0.98 g of diatrizoate. Endoscopists performing ERCP should be aware of the likelihood of systemic absorption and the possibility of reactions to iodinated contrast materials in sensitive patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6884166     DOI: 10.1007/bf01296902

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

1.  Pharmacological and toxicological studies on Triosil, an intravenous contrast agent.

Authors:  D BUSFIELD; K J CHILD; E G TOMICH
Journal:  Br J Radiol       Date:  1962-12       Impact factor: 3.039

2.  The influence of different contrast media for cholegraphy on blood pressure and pulse rate.

Authors:  G F SALTZMAN; K A SUNDSTROM
Journal:  Acta radiol       Date:  1960-11       Impact factor: 1.990

3.  Endoscopic retrograde cholangiopancreatography (ERCP): radiographic technique.

Authors:  H I Goldberg; M K Bilbao; E T Stewart; C A Rohrmann; A A Moss
Journal:  Am J Dig Dis       Date:  1976-03

4.  Route of flow and micropathology resulting from retrograde intrabiliary injection of India ink and ferritin in experimental animals. A combined light- and electron-microscopic study.

Authors:  D E Bockman
Journal:  Gastroenterology       Date:  1974-08       Impact factor: 22.682

5.  Demonstration of a retrograde pancreatic pathway: correlation of roentgenographic and electron microscopic studies.

Authors:  R L Waldron; S A Luse; H E Wollowick; W B Seaman
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1971-04

6.  Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases.

Authors:  M K Bilbao; C T Dotter; T G Lee; R M Katon
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey.

Authors:  W H Shehadi
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1975-05

8.  Contrast absorption and pancreatic inflammation following experimental ERCP.

Authors:  L Kivisaari
Journal:  Invest Radiol       Date:  1979 Nov-Dec       Impact factor: 6.016

  8 in total
  3 in total

1.  Relationship of biliary pressure to cholangiovenous reflux during endoscopic retrograde balloon catheter cholangiography.

Authors:  H Yoshimoto; S Ikeda; M Tanaka; S Matsumoto
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

2.  Serum diatrizoate level during intraoperative cholangiography in patients without choledochal obstructions.

Authors:  K Sakahira; T Ebata; Y Tsunoda; K Amaha; K Meno
Journal:  Dig Dis Sci       Date:  1990-09       Impact factor: 3.199

3.  Risk Evaluation of Endoscopic Retrograde Cholangiopancreatography-Related Contrast Media Allergic-Like Reaction: A Single Centre Experience.

Authors:  Félix Trottier-Tellier; Laurence Harvey; Jean-Daniel Baillargeon
Journal:  Can J Gastroenterol Hepatol       Date:  2018-02-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.